SF

Stephan Fischer

BO BOE: 13 patents #1,567 of 12,373Top 15%
EC Eveready Battery Company: 12 patents #41 of 520Top 8%
MA Maxygen: 6 patents #21 of 110Top 20%
EB Edgewell Personal Care Brands: 5 patents #20 of 150Top 15%
RA Roche Palo Alto: 5 patents #73 of 347Top 25%
Hoffmann-La Roche: 4 patents #813 of 3,238Top 30%
BMW: 3 patents #776 of 5,361Top 15%
SB Sanofi Biotechnology: 3 patents #13 of 74Top 20%
RG Roche Diagnostics Gmbh: 2 patents #166 of 851Top 20%
SG Sms Group Gmbh: 2 patents #79 of 401Top 20%
MA Man Roland Druckmaschinen Ag: 1 patents #292 of 592Top 50%
CG Ca-Digital Gmbh: 1 patents #2 of 6Top 35%
SS Sms Schloemann-Siemag: 1 patents #170 of 376Top 50%
SA Sms Siemag Ag: 1 patents #142 of 318Top 45%
TK Trumpf Werkzeugmaschinen Se + Co. Kg: 1 patents #17 of 53Top 35%
UK Unify Gmbh & Co. Kg: 1 patents #123 of 172Top 75%
AM Amazon: 1 patents #10,608 of 19,158Top 60%
📍 Hiddenhausen, DE: #1 of 41 inventorsTop 3%
Overall (All Time): #30,515 of 4,157,543Top 1%
68
Patents All Time

Issued Patents All Time

Showing 51–68 of 68 patents

Patent #TitleCo-InventorsDate
D524483 Guard bar Jay Bunnell, Michael O'Malley, Jochen Thoene 2006-07-04
D524482 Guard bar Jochen Thoene 2006-07-04
6993951 Bending device for the working rolls of a hot-rolling frame Peter Sudau, Heinz-Adolf Müller 2006-02-07
6270988 Process for producing recombinant proteins using a gene for tRNA Ulrich Brinkmann, Ralf Mattes 2001-08-07
5973118 Mutant of the Erythrina caffra type inhibitor and the use of the said mutant for purifying serine proteases Ulrich Kohnert, Anne Stern, Manfred Wozny 1999-10-26
5958722 Use of recombinant inhibitor from Erythrina caffra for purifying serine proteases Ulrich Kohnert, Anne Stern 1999-09-28
5908625 Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases Ulrich Kohnert, Anne Stern, Ulrich Martin 1999-06-01
5854048 Method for treating thromboembolic conditions using thrombolytically active proteins Ulrich Martin 1998-12-29
5747030 Pharmaceutical preparation containing plasminogen activators Ulrich Kohnert, Hans-Jorg Markl, Heinrich Woog 1998-05-05
5723122 Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases Ulrich Kohnert, Anne Stern, Ulrich Martin 1998-03-03
5676947 Method for treating thromboembolic conditions using thrombolytically active proteins Ulrich Martin 1997-10-14
5593865 Process for the activating of gene-technologically produced, heterologous, disulphide bridge-containing eukaryotic proteins after expression in prokaryotes Rainer Rudolph, Ralf Mattes 1997-01-14
5510330 Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof. Ulrich Martin 1996-04-23
5453363 Process for the activation of t-PA or Ing after genetic expression in prokaryotes Rainer Rudolph, Ralf Mattes 1995-09-26
5312743 Cholesterol esterases with variable substrate specificity Gunther Schumacher, Christian Hanke 1994-05-17
5223256 Thrombolytically active non-glycosylated protein Anne Stern, Ulrich Kohnert, Rainer Rudolph, Ulrich Martin 1993-06-29
5169758 Stabilized, NAD(P)H-dependent, soluble nitrate reductase, a process for the preparation thereof and a reagent containing it Barbel Wurst, Hans-Otto Beutler, Georg-Burkhard Kresse, Herwig Brunner 1992-12-08
4933434 Process for obtaining renatured proteins Rainer Rudolph 1990-06-12